Wall Street Zen Upgrades Definium Therapeutics (NASDAQ:DFTX) to “Hold”

Definium Therapeutics (NASDAQ:DFTX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

A number of other brokerages have also recently commented on DFTX. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Canaccord Genuity Group set a $58.00 price target on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Oppenheimer set a $60.00 price objective on shares of Definium Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Finally, Needham & Company LLC lifted their price objective on shares of Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Definium Therapeutics presently has a consensus rating of “Buy” and an average target price of $52.36.

Definium Therapeutics Trading Down 1.2%

NASDAQ:DFTX opened at $42.65 on Friday. The stock’s 50 day moving average price is $34.09 and its 200 day moving average price is $24.10. The company has a market capitalization of $4.25 billion, a PE ratio of -17.13 and a beta of 2.20. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics has a 52-week low of $7.96 and a 52-week high of $49.20.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.23). On average, research analysts anticipate that Definium Therapeutics will post -2.27 EPS for the current year.

Insider Buying and Selling

In related news, CEO Robert Barrow sold 29,208 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the transaction, the chief executive officer directly owned 1,098,246 shares in the company, valued at $49,454,017.38. This trade represents a 2.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Brandi Roberts sold 3,013 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the transaction, the chief financial officer directly owned 209,487 shares in the company, valued at $9,433,199.61. This represents a 1.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 48,096 shares of company stock valued at $2,165,763. Company insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

Several hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its holdings in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after acquiring an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after purchasing an additional 3,020 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new stake in Definium Therapeutics in the fourth quarter valued at about $117,000. Caxton Associates LLP acquired a new stake in Definium Therapeutics in the third quarter valued at about $126,000. Finally, Mercer Global Advisors Inc. ADV boosted its holdings in Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after purchasing an additional 2,079 shares in the last quarter. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.